Apremilast (Systemic)

Brand names: Otezla
Drug class: Antineoplastic Agents

Usage of Apremilast (Systemic)

Psoriatic Arthritis

Management of active psoriatic arthritis in adults.

Various drugs and drug classes are used to treat psoriatic arthritis. Apremilast is considered an oral small molecule (OSM), which is one of several classes of disease-modifying treatments for this condition.

The American College of Rheumatology (ACR)/National Psoriasis Foundation guideline conditionally recommends the use of TNF blocking agents over OSMs in treatment-naive patients with active psoriatic arthritis; however, an OSM such as apremilast may be considered in treatment-naive patients without severe psoriasis or psoriatic arthritis, in those who prefer oral over parenteral therapy, and those with contraindications to TNF blocking therapy (e.g., CHF, previous serious infection, recurrent infections, demyelinating disease).

In patients not responding to treatment with an OSM, switching to another OSM is generally recommended over adding another OSM to the current regimen except in the case of apremilast since evidence of benefit with this drug is mostly with combination therapy. Switching to apremilast monotherapy may be considered instead of apremilast combination therapy if the patient has intolerable adverse events with the current OSM.

Recommendations for use and selection of disease-modifying therapies in psoriatic arthritis vary based on the presence of certain disease characteristics (e.g., psoriatic spondylitis/axial disease, enthesitis) and comorbidities (e.g., inflammatory bowel disease, diabetes).

Plaque Psoriasis

Management of plaque psoriasis in adults who are candidates for phototherapy or systemic therapy.

Various drugs and drug classes are used to treat psoriasis including systemic biologic and nonbiologic therapies; apremilast is a nonbiologic option for treatment of this condition.

Guidelines generally recommend apremilast for treatment of adults with moderate to severe psoriasis; also may be used to augment efficacy of certain biologic agents (e.g., adalimumab, etanercept, infliximab, ustekinumab).

Recommendations for use and selection of psoriasis therapies vary based on patient age, disease characteristics (e.g., severity, location, presence of psoriatic arthritis), and comorbidities (e.g., inflammatory bowel disease).

Oral Ulcers Associated with Behçet Disease

Management of oral ulcers associated with Behçet disease in adults.

Treatment of Behçet disease is determined by involved organs, severity and duration of disease, age, gender, frequency of attacks, and patient preferences. The European Alliance of Associations for Rheumatology (EULAR) guidelines recommend topical treatments (such as steroids) and colchicine for mucocutaneous lesions. Apremilast can be considered as an alternative to colchicine in selected patients who have recurrent lesions despite colchicine use.

Relate drugs

How to use Apremilast (Systemic)

General

Pretreatment Screening

  • Evaluate renal function prior to starting apremilast; dosage reductions are recommended for severe renal impairment.
  • Weigh the risks and benefits of apremilast therapy in patients with a history of depression and/or suicidal thoughts or behaviors.

    • Patient Monitoring

  • Monitor patients for the potential development of serious hypersensitivity reactions including anaphylaxis and angioedema.
  • Monitor patients for diarrhea, nausea, and vomiting.
  • Monitor for emergence or worsening of depression, suicidal thoughts or other mood changes.
  • Monitor weight regularly; consider discontinuing apremilast if unexplained or clinically significant weight loss occurs.

    • Administration

    Oral Administration

    Administer orally without regard to meals.

    Swallow tablets intact. Do not crush, split, or chew.

    Dosage

    Adults

    Psoriatic Arthritis Oral

    Initiate at a dosage of 10 mg daily and titrate as follows (over 5 days in increments of 10 mg daily) to reduce the risk of GI symptoms:

  • 10 mg in the morning on day 1
  • 10 mg in the morning and 10 mg in the evening on day 2
  • 10 mg in the morning and 20 mg in the evening on day 3
  • 20 mg in the morning and 20 mg in the evening on day 4
  • 20 mg in the morning and 30 mg in the evening on day 5, and 30 mg twice daily thereafter

    • Maintenance dosage: 30 mg twice daily.

    Plaque Psoriasis Oral

    Initiate at a dosage of 10 mg daily and titrate as follows (over 5 days in increments of 10 mg daily) to reduce the risk of GI symptoms:

  • 10 mg in the morning on day 1
  • 10 mg in the morning and 10 mg in the evening on day 2
  • 10 mg in the morning and 20 mg in the evening on day 3
  • 20 mg in the morning and 20 mg in the evening on day 4
  • 20 mg in the morning and 30 mg in the evening on day 5, and 30 mg twice daily thereafter

    • Maintenance dosage: 30 mg twice daily.

    Oral Ulcers Associated with Behçet Disease Oral

    Initiate at a dosage of 10 mg daily and titrate as follows (over 5 days in increments of 10 mg daily) to reduce the risk of GI symptoms.

  • 10 mg in the morning on day 1
  • 10 mg in the morning and 10 mg in the evening on day 2
  • 10 mg in the morning and 20 mg in the evening on day 3
  • 20 mg in the morning and 20 mg in the evening on day 4
  • 20 mg in the morning and 30 mg in the evening on day 5, and 30 mg twice daily thereafter

    • Maintenance dosage: 30 mg twice daily.

    Special Populations

    Hepatic Impairment

    No dosage adjustment required.

    Renal Impairment

    Severe renal impairment (Clcr <30 mL/minute): Maintenance dosage of 30 mg once daily. Initiate at a dosage of 10 mg daily and titrate as follows to reduce the risk of GI symptoms:

  • 10 mg in the morning for 3 days (days 1, 2, and 3)
  • 20 mg in the morning for 2 days (days 4 and 5)
  • 30 mg once daily thereafter

    • Geriatric Patients

    Manufacturer makes no specific dosage recommendations.

    Warnings

    Contraindications

  • Known hypersensitivity to apremilast or any ingredient in the formulation.

    • Warnings/Precautions

    Hypersensitivity

    Hypersensitivity reactions including cases of angioedema and anaphylaxis reported. Avoid use in patients with a known hypersensivity to the drug of any of its excipients.

    Discontinue if signs or symptoms of serious hypersensitivity reactions occur and initiate appropriate therapy.

    GI Effects

    Severe diarrhea, nausea, and vomiting reported.

    Monitor patients who are more susceptible to complications, such as patients ≥65 years of age and those taking drugs that can lead to volume depletion or hypotension.

    Reduce apremilast dosage or suspend therapy if patients develop severe diarrhea, nausea, or vomiting.

    Depression and Suicidality

    Depression, depressed mood, and suicidal ideation/behaviors reported.

    Carefully weigh risks and benefits prior to using apremilast in patients with a history of depression and/or suicidal thoughts or behavior. Carefully evaluate the risks and benefits of continuing therapy if such effects occur.

    Weight Loss

    Weight loss of ≥5–10% of body weight reported.

    Regularly monitor patient’s weight. If unexplained or clinically important weight loss occurs, evaluate weight loss and consider discontinuing apremilast.

    Interactions

    Concomitant use of potent CYP inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin) not recommended.

    Specific Populations

    Pregnancy

    Pregnancy registry at [Web]877-311-8972 or .

    Increases in spontaneous abortion and embryofetal death reported in animal reproduction studies.

    Lactation

    Distributed into milk in mice; not known whether distributed into human milk.

    Consider the benefits of breast-feeding and the importance of apremilast to the patient along with potential adverse effects on the breast-fed infant from the drug or underlying maternal condition.

    Pediatric Use

    Safety and efficacy not established in pediatric patients <18 years of age.

    Geriatric Use

    No overall differences in safety observed between geriatric and younger adults with psoriatic arthritis.

    No overall differences in efficacy and safety observed between geriatric and younger adults with plaque psoriasis.

    Monitor patients ≥65 years of age closely for volume depletion or hypotension resulting from treatment-related severe diarrhea, nausea, or vomiting.

    Hepatic Impairment

    Moderate or severe hepatic impairment (Child-Pugh class B or C) does not alter pharmacokinetics of apremilast. No dosage adjustment necessary.

    Renal Impairment

    Systemic exposure increased in patients with severe renal impairment (Clcr <30 mL/minute). Reduced dosage recommended.

    Common Adverse Effects

    Adverse events reported in ≥5% of patients with psoriatic arthritis: Diarrhea, nausea, and headache.

    Adverse events reported in ≥5% of patients with psoriasis: Diarrhea, nausea, upper respiratory tract infection, and headache (including tension headache).

    Adverse effects reported in ≥10% of patients with Behçet disease: Diarrhea, nausea, headache, and upper respiratory tract infection.

    What other drugs will affect Apremilast (Systemic)

    Undergoes oxidative metabolism (mediated mainly by CYP3A4, with minor contributions from CYP1A2 and CYP2A6) with subsequent glucuronidation; also undergoes non-CYP-mediated hydrolysis.

    Does not inhibit CYP isoenzyme 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4 in vitro; does not induce CYP isoenzyme 1A2, 2B6, 2C9, 2C19, or 3A4 in vitro.

    A substrate but not an inhibitor of P-glycoprotein (P-gp) in vitro; neither a substrate nor inhibitor of organic anion transporters (OAT) 1 and 3, organic anion transporting polypeptides (OATP) 1B1 and 1B3, organic cation transporter (OCT) 2, or breast cancer resistance protein (BCRP) in vitro.

    Drugs Affecting Hepatic Microsomal Enzymes

    Potent CYP inducers: Reduced systemic exposure and possible loss of efficacy of apremilast; concomitant use not recommended.

    Specific Drugs

    Drug

    Interaction

    Comments

    Anticonvulsants (carbamazepine, phenobarbital, phenytoin)

    Systemic exposure and efficacy of apremilast may be reduced

    Concomitant use not recommended

    Estrogens/progestins

    Contraceptive containing ethinyl estradiol and norgestimate: No substantial pharmacokinetic interaction

    Ketoconazole

    No clinically important effects on apremilast exposure

    Methotrexate

    No substantial effects on pharmacokinetics of either drug

    Rifampin

    Reduced apremilast AUC and peak plasma concentration; possible loss of apremilast efficacy

    Concomitant use not recommended

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant